Smith & Nephew plc today announced the appointment of Namal Nawana as Chief Executive Officer. He will join the Company and be appointed to the Board as an Executive Director on 7 May 2018.
https://european-biotechnology.com/wp-content/uploads/2024/04/2018_appointments_namalnawana.jpg400400h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-04-04 14:29:332018-04-04 14:29:33Namal Nawana appointed CEO of Smith & Nephew
Rutger Oudejans, Brand Director at bioLIVE, postulates that the bio supply chain could learn some lessons from the small molecules sector. The bio industry continues to expand at rates above the traditional NCE (New Chemical Entity) sector, yet for the supply chain there are vital synergies that could help further accelerate developments.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_spring_2018_Rutger_Oudejans.jpg5621000Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-04-04 00:00:002024-04-02 16:21:25Learning from the small molecule supply chain
French allogenic CAR-T cell therapy developer Cellectis is set to launch an underwritten public offering of $175m of its American Depositary Shares (ADS), each representing one ordinary share of Cellectis.
https://european-biotechnology.com/wp-content/uploads/2024/04/Cellectis-CAR_T.jpg8001200Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-04-03 18:44:152018-04-03 18:44:15Cellectis in offering of US$175m ADS following asset swap
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of Carsten Thiel, Ph.D., as Chief Executive Officer.
https://european-biotechnology.com/wp-content/uploads/2024/04/csm_carsten-thiel_f88a4077c6.jpg282282h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-04-03 11:00:512018-04-03 11:00:51Abeona Therapeutics Appoints Carsten Thiel as CEO
Motif Bio has initiated a NDA rolling submission for iclaprim, a Gram-positive-targeted investigational antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in high-risk MRSA (Methicillin-resistant S. aureus) patients.
https://european-biotechnology.com/wp-content/uploads/2024/04/Ebi_3fra_deposited_chain_front_image-800x800.png800800Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-04-03 08:26:332018-04-03 08:26:33Motif Bio to submit NDA for iclaprim
https://european-biotechnology.com/wp-content/uploads/2024/04/tk_11_2017_ute_kilger_16x9.jpg293520h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-04-01 14:42:002018-04-01 14:42:00Balancing generic and innovative medical uses
Rentschler Biopharma SE announced today that Dr. Thomas Rösch will join the Company as Vice President Biopharma Engineering & Technology, effective April 1, 2018. He will be responsible for advanced biopharmaceutical engineering projects to enhance site and capacity.
https://european-biotechnology.com/wp-content/uploads/2024/04/RentschlerBiopharma_ThomasRoesch.jpg400400h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-03-29 10:51:392018-03-29 10:51:39Rentschler appoints Dr. Thomas Rösch
Japanese drug giant Takeda Pharmaceutical Co. Ltd. has confirmed its intention to make a bid for orphan drug leader and neurology specialist Shire plc. The take-over offer has to be made until 25 April.
https://european-biotechnology.com/wp-content/uploads/2024/04/shire_HAE.jpg388513Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-03-29 08:58:482018-03-29 08:58:48Takeda announced bid for Shire
Roche’s US arm Genentech has confirmed a total of 5 deaths in adult patients who were dosed with its to-be hemophilia blockbuster emicizumab (Hemlibra), a BITE antibody that mimics the effect of Factor VIII which lack patients with hemophilia A.
More than 400 experts came together at the World Bio Market Conference in Amsterdam to discuss the challenges of successfully implementing bio-based business strategies.
Namal Nawana appointed CEO of Smith & Nephew
AppointmentsSmith & Nephew plc today announced the appointment of Namal Nawana as Chief Executive Officer. He will join the Company and be appointed to the Board as an Executive Director on 7 May 2018.
Learning from the small molecule supply chain
BackgroundRutger Oudejans, Brand Director at bioLIVE, postulates that the bio supply chain could learn some lessons from the small molecules sector. The bio industry continues to expand at rates above the traditional NCE (New Chemical Entity) sector, yet for the supply chain there are vital synergies that could help further accelerate developments.
Cellectis in offering of US$175m ADS following asset swap
Latest NewsFrench allogenic CAR-T cell therapy developer Cellectis is set to launch an underwritten public offering of $175m of its American Depositary Shares (ADS), each representing one ordinary share of Cellectis.
Abeona Therapeutics Appoints Carsten Thiel as CEO
AppointmentsAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of Carsten Thiel, Ph.D., as Chief Executive Officer.
Motif Bio to submit NDA for iclaprim
Latest NewsMotif Bio has initiated a NDA rolling submission for iclaprim, a Gram-positive-targeted investigational antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in high-risk MRSA (Methicillin-resistant S. aureus) patients.
Balancing generic and innovative medical uses
OpinionIs cheaper always better when it comes to generics? What about when it comes to innovative medical uses of them?
Rentschler appoints Dr. Thomas Rösch
AppointmentsRentschler Biopharma SE announced today that Dr. Thomas Rösch will join the Company as Vice President Biopharma Engineering & Technology, effective April 1, 2018. He will be responsible for advanced biopharmaceutical engineering projects to enhance site and capacity.
Takeda announced bid for Shire
Latest NewsJapanese drug giant Takeda Pharmaceutical Co. Ltd. has confirmed its intention to make a bid for orphan drug leader and neurology specialist Shire plc. The take-over offer has to be made until 25 April.
Roche reports 5 deaths after dosing of Hemlibra
Latest NewsRoche’s US arm Genentech has confirmed a total of 5 deaths in adult patients who were dosed with its
to-be hemophilia blockbuster emicizumab (Hemlibra), a BITE antibody that mimics the effect of Factor VIII which lack patients with hemophilia A.
From biorefineries to consumer goods
Latest NewsMore than 400 experts came together at the World Bio Market Conference in Amsterdam to discuss the challenges of successfully implementing bio-based business strategies.